title: [Influence of cytoflavin on symptoms of asthenia, emotional disorders and autonomic regulation in patients with organic asthenic disorder].
abstract: The present observational study addressed effects of cytoflavine on symptoms of asthenia and emotional and autonomic regulation in patients with organic emotional-labile (asthenic) disorder (F06.6). Fifty one females and 49 males (mean age 36.8±11.0 years) were included into the study during their in-patient treatment in Moscow Research and Clinical Center for Neuropsychiatry of the Healthcare Department. All patients received standard antidepressant and vascular therapy, were consulted by psychologists or psychotherapists, visited physiotherapeutic procedures, massage and medical physical training. In addition, 50 patients received cytoflavin two tablets twice per day. At the psychiatric re-assessment before discharge both cytoflavin and control groups showed similar significant reduction of asthenia symptoms. At the same time, patients with cognitive deficits showed significantly larger improvement of cognitive functions after cytoflavin treatment in comparison with cognitively deficient patients after only standard therapy. Improvement of depressive symptoms was significantly larger in cytoflavin group in comparison with controls as well. These data are consistent with previous studies which showed cytoflavin to be effective as a treatment for patients with cognitive deficits and organic depression.
authors.forename: A G
authors.initials: AG
authors.lastname: Polunina
authors.forename: N A
authors.initials: NA
authors.lastname: Osinovskaia
authors.forename: A N
authors.initials: AN
authors.lastname: Gudkova
authors.forename: A B
authors.initials: AB
authors.lastname: Gekht
mesh_terms: D000328:Adult; D001247:Asthenia / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D001341:Autonomic Nervous System / Q000187:drug effects; D004338:Drug Combinations; D004644:Emotions / Q000187:drug effects; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009536:Niacinamide / Q000627:therapeutic use*; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D018696:Neuroprotective Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate